2-Imidazol-1-yl-3,3-bis(methylsulfonyl)prop-2-enenitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-Imidazol-1-yl-3,3-bis(methylsulfonyl)prop-2-enenitrile
• 英文别名: 2-imidazol-1-yl-3,3-bis(methylsulfonyl)prop-2-enenitrile
• 化学式: C₈H₉N₃O₄S₂
• 分子量: 275.3
• InChiKey: KKKISKYXNRVFHC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  127
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• METHOD OF EVALUATING PHARMACEUTICAL PREPARATION CONTAINING LULICONAZOLE AND INDEX SUBSTANCE
  申请人：POLA PHARMA INC.

  公开号：US20150168357A1

  公开（公告）日：2015-06-18

  Disclosed is a method of evaluating stability of a pharmaceutical preparation containing luliconazole. The method includes measuring an amount of production of an SE form of luliconazole represented by following formula (2), an amount of production of a Z form of luliconazole represented by following formula (3) and an amount of production of an amide form of luliconazole represented by following formula (1) after storage under a severe condition or an accelerated condition, and judging that the stability of the pharmaceutical preparation is high if each of the amount of production of the SE form, the amount of production of the Z form and the amount of production of the amide form is not more than 5% by weight with respect to a compounded amount of luliconazole.
• PHARMACEUTICAL COMPOSITION FOR DISEASES CAUSED BY PATHOGENIC MICROORGANISMS SUCH AS CANDIDA
  申请人：POLA PHARMA INC.

  公开号：US20150352078A1

  公开（公告）日：2015-12-10

  An object is to provide means for precisely treating vaginitis caused by intracellular parasite, protozoa, and/or fungus. A pharmaceutical composition for vaginitis, comprising a compound represented by the following general formula (1) as an active ingredient: (1) (In the formula, R represents a halogen atom or a hydrogen atom, and X represents a halogen atom.)
• PHARMACEUTICAL COMPOSITION FOR DISEASES CAUSED BY PATHOGENIC MICROORGANISMS SUCH AS ASPERGILLUS
  申请人：POLA PHARMA INC.

  公开号：US20150366845A1

  公开（公告）日：2015-12-24

  An object is to provide means for precisely treating pneumonia caused by intracellular parasite, protozoa, and/or fungus. A pharmaceutical composition for pneumonia, comprising a compound represented by the following general formula (1) as an active ingredient: (In the formula, R represents a halogen atom or a hydrogen atom, and X represents a halogen atom.)
• CRYSTAL HAVING SPECIFIC CRYSTAL HABIT AND PHARMACEUTICAL COMPOSITION CONTAINING THE CRYSTAL AS ACTIVE INGREDIENT
  申请人：POLA PHARMA INC.

  公开号：US20160168136A1

  公开（公告）日：2016-06-16

  An object is to provide a crystal having a new crystal habit of luliconazole and expand the possibility of application to pharmaceuticals. Disclosed is a crystal of luliconazole having such a crystal habit that (020) plane is a specific crystal growth surface.
• PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PNEUMONIA ASSOCIATED WITH FUSARIUM FUNGUS
  申请人：POLA PHARMA INC.

  公开号：US20160279101A1

  公开（公告）日：2016-09-29

  The present invention aims to provide a pharmaceutical composition for pneumonia associated at least with a Fusarium fungus as a causative microorganism. Provided is a pharmaceutical composition for pneumonia associated at least with a Fusarium fungus as a causative microorganism, which pharmaceutical composition includes as an effective component a compound represented by the General Formula (1) below: (wherein R represents a halogen atom or hydrogen atom, and X represents a halogen atom).